Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally

Avidity Partners Management disclosed a buy of 100,000 shares of Oruka Therapeutics (NASDAQ:ORKA) in a May 13, 2026, SEC filing, with an estimated transaction value of $3.48 million based on quarterly average pricing.Avidity Partners Management reported purchasing 100,000 additional shares of Oruka Therapeutics, according to a Securities and Exchange Commission (SEC) filing dated May 13, 2026. The estimated transaction value was $3.48 million, calculated using the average closing price during the first quarter of 2026. The fund's quarter-end position value in Oruka Therapeutics rose by $32.00 million, a figure that includes both the share increase and changes in market price.Oruka Therapeutics is a clinical-stage biotechnology company specializing in innovative monoclonal antibody therapies for immunology and inflammation. With a lean workforce and a focused pipeline, the company is positioned to address unmet medical needs in psoriasis and related conditions. Its strategy emphasizes novel biologic development to achieve competitive differentiation in the biopharmaceutical sector.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool